Sep. 22, 2004 Philadelphia, PA – Researchers at the University of Pennsylvania School of Medicine report a novel strategy for stimulating the production of utrophin – an important muscle protein in young mice – for muscular dystrophy therapy. The investigators gave mdx mice (the mouse model for Duchenne's muscular dystrophy) heregulin, a small molecule to turn on the production of utrophin in their muscles. Utrophin improved muscle function in the mdx mice. "Our strategy boosts the levels of an existing gene using pre-existing cellular machinery rather than having to deliver a gene via gene therapy," says lead author Tejvir S. Khurana, MD, PhD, Assistant Professor of Physiology & Member of the Pennsylvania Muscle Institute.
They detected an approximately threefold increase of utrophin levels over control mdx mice. "This is the level at which one starts seeing a therapeutic affect, as measured in lab tests with mouse muscles," says Khurana. The researchers noted an improvement in the quality of mouse muscle tissue, the biomechanical properties of muscles, and biochemical indices of dystrophy in the muscles.
In patients with Duchenne's muscular dystrophy (DMD), the gene to make the protein dystrophin is missing, which results in the muscle wasting that is associated with the disease. The progressive muscle wasting begins in early childhood and typically leads to death in the twenties. "The gene for utrophin is already in the body, so by giving a small peptide to stimulate its production, we're bypassing the need for dystrophin by cranking up the levels of utrophin," explains Khurana. This research appears in the September 21 issue of the Proceedings of the National Academy of Sciences.
Utrophin (also called dystrophin-related protein) is found on chromosome 6 and functions much the same as dystrophin, which is found on the X chromosome. However, utrophin is made in large amounts in fetal muscles, after which dystrophin takes over throughout adult life as one of the main muscle-membrane-associated proteins. "This approach reawakens the body to make utrophin again," says Khurana. "And it doesn't preclude possible gene-therapy treatments for muscular dystrophy. Utrophin enrichment is a parallel strategy with great potential of being used in combination with other approaches."
Despite these advances in an animal model of DMD, Khurana sounds a cautionary note for near-term clinical applications: "There are a number of good reasons for parents not to start thinking of giving their children heregulin at present; for one, we don't know anything about its potential toxicity or side effects." He stresses that this approach needs to first be properly tested in controlled trials to measure its possible long-term toxicity and efficacy in mdx mice, and then in additional animal-model studies.
This work was funded in part by grants from Association Française contre les Myopathies (France), Duchenne Parents Project (The Netherlands), Lundbeckfonden (Denmark), as well as by the National Institutes of Health. Other Penn researchers contributing to this study are Thomas O.B. Krag, Sasha Bogdanovich, and M. Dominik Fischer, along with Elisabeth H. Javazon and Alan W. Flake from the Children's Hospital of Philadelphia and Claus Juel, Jacob Hansen-Schwartz, and Lars Edvinsson from the Glostrup Hospital & University of Copenhagen, Denmark.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.